Back to search results

Observational Study on Growth Hormone and Beta-cells in Gestational Diabetes

This study at the University of Missouri is looking into how beta-cells (cells in your pancreas that make insulin to control blood sugar) respond to growth hormone. Researchers want to understand why some people develop gestational diabetes (high blood sugar during pregnancy) by studying women who have had it, compared to women who haven't. They will measure beta-cell function before and 7 days after giving rhGH (recombinant human growth hormone). You may be able to join if you are a woman between 18 and 45 years old, had a full-term pregnancy in the last 5 years, and have a BMI between 18.5 and 45. The study aims to enroll 30 participants.

Study design
This is an observational study aiming to enroll 30 women. It compares women with a history of gestational diabetes to a control group without this history.
What's involved
Beta-cell function will be measured before and 7 days after rhGH administration.
Compensation
Not stated in the trial record.
Follow-up
Beta-cell function is measured before and 7 days after rhGH administration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06571487

Growth Hormone Resistance of Beta-cells A

Recruiting
Not specifiedAges 18–45Observational
University of Missouri-Columbia
~30 participants
Updated 2026-05-11 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Beta-cell function
Measured over before and 7 days after rhGH administration

Conditions

Gestational Diabetes
Obesity
Healthy

Explore related trials

Gestational DiabetesHealthyObesity

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Bettina Mittendorfer, PhD · PRINCIPAL_INVESTIGATOR · University of Missouri-Columbia

Who to contact

Amanda Heider
[email protected]
573-884-6852
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Singleton, full term pregnancy within the past 5 years
Body mass index ≥18.5 kg/m2 and \<45.0 kg/m2
Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy
Control Group: no history of gestational diabetes

Exclusion

Pregnant, planning to become pregnant during the study, or breastfeeding
Current diagnosis or history of type 1 or type 2 diabetes
Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
History of bariatric surgery
Known, uncontrolled hypothyroidism
History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
Current cancer or cancer that has been in remission less than 5 years
First degree relative with diabetes diagnosis
Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

What this trial measures

  • Beta-cell functionbefore and 7 days after rhGH administration

    Insulin secretion rate in relationship to plasma glucose